Literature DB >> 25469265

ERG oncoprotein expression in prostate carcinoma patients of different ethnicities.

Gregory M Kelly1, Yink Heay Kong1, Albert Dobi2, Shiv Srivastava2, Isabell A Sesterhenn3, Rajadurai Pathmanathan4, Hui Meng Tan5, Shyh-Han Tan2, Sok Ching Cheong1.   

Abstract

Overexpression of the erythroblast transformation-specific-related gene (ERG) oncoprotein due to transmembrane protease, serine 2 (TMPRSS2)-ERG fusion, the most prevalent genomic alteration in prostate cancer (CaP), is more frequently observed among Caucasian patients compared to patients of African or Asian descent. To the best of our knowledge, this is the first study to investigate the prevalence of ERG alterations in a multiethnic cohort of CaP patients. A total of 191 formalin-fixed paraffin-embedded sections of transrectal ultrasound-guided prostate biopsy specimens, collected from 120 patients treated at the Sime Darby Medical Centre, Subang Jaya, Malaysia, were analyzed for ERG protein expression by immunohistochemistry using the anti-ERG monoclonal antibody 9FY as a surrogate for the detection of ERG fusion events. The overall frequency of ERG protein expression in the population evaluated in this study was 39.2%. Although seemingly similar to rates reported in other Asian communities, the expression of ERG was distinct amongst different ethnic groups (P=0.004). Malaysian Indian (MI) patients exhibited exceedingly high expression of ERG in their tumors, almost doubling that of Malaysian Chinese (MC) patients, whereas ERG expression was very low amongst Malay patients (12.5%). When collectively analyzing data, we observed a significant correlation between younger patients and higher ERG expression (P=0.04). The prevalence of ERG expression was significantly different amongst CaP patients of different ethnicities. The higher number of ERG-expressing tumors among MI patients suggested that the TMPRSS2-ERG fusion may be particularly important in the pathogenesis of CaP amongst this group of patients. Furthermore, the more frequent expression of ERG among the younger patients analyzed suggested an involvement of ERG in the early onset of CaP. The results of this study underline the value of using ERG status to better understand the differences in the etiology of CaP initiation and progression between ethnic groups.

Entities:  

Keywords:  Malaysia; prostate cancer; serine 2-erythroblast transformation-specific-related gene fusion; transmembrane protease

Year:  2014        PMID: 25469265      PMCID: PMC4251096          DOI: 10.3892/mco.2014.418

Source DB:  PubMed          Journal:  Mol Clin Oncol        ISSN: 2049-9450


  47 in total

1.  A common variant associated with prostate cancer in European and African populations.

Authors:  Laufey T Amundadottir; Patrick Sulem; Julius Gudmundsson; Agnar Helgason; Adam Baker; Bjarni A Agnarsson; Asgeir Sigurdsson; Kristrun R Benediktsdottir; Jean-Baptiste Cazier; Jesus Sainz; Margret Jakobsdottir; Jelena Kostic; Droplaug N Magnusdottir; Shyamali Ghosh; Kari Agnarsson; Birgitta Birgisdottir; Louise Le Roux; Adalheidur Olafsdottir; Thorarinn Blondal; Margret Andresdottir; Olafia Svandis Gretarsdottir; Jon T Bergthorsson; Daniel Gudbjartsson; Arnaldur Gylfason; Gudmar Thorleifsson; Andrei Manolescu; Kristleifur Kristjansson; Gudmundur Geirsson; Helgi Isaksson; Julie Douglas; Jan-Erik Johansson; Katarina Bälter; Fredrik Wiklund; James E Montie; Xiaoying Yu; Brian K Suarez; Carole Ober; Kathleen A Cooney; Henrik Gronberg; William J Catalona; Gudmundur V Einarsson; Rosa B Barkardottir; Jeffrey R Gulcher; Augustine Kong; Unnur Thorsteinsdottir; Kari Stefansson
Journal:  Nat Genet       Date:  2006-05-07       Impact factor: 38.330

2.  Admixture mapping identifies 8q24 as a prostate cancer risk locus in African-American men.

Authors:  Matthew L Freedman; Christopher A Haiman; Nick Patterson; Gavin J McDonald; Arti Tandon; Alicja Waliszewska; Kathryn Penney; Robert G Steen; Kristin Ardlie; Esther M John; Ingrid Oakley-Girvan; Alice S Whittemore; Kathleen A Cooney; Sue A Ingles; David Altshuler; Brian E Henderson; David Reich
Journal:  Proc Natl Acad Sci U S A       Date:  2006-08-31       Impact factor: 11.205

3.  Is Kelantan joining the global cancer epidemic?--experience from hospital Universiti Sains Malaysia; 1987-2007.

Authors:  Nor Hayati Othman; Zaini Mohd Nor; Biswa Mohan Biswal
Journal:  Asian Pac J Cancer Prev       Date:  2008 Jul-Sep

4.  ERG rearrangement and protein expression in the progression to castration-resistant prostate cancer.

Authors:  J R Gsponer; M Braun; V J Scheble; T Zellweger; A Bachmann; S Perner; T Vlajnic; M Srivastava; S H Tan; A Dobi; I A Sesterhenn; S Srivastava; L Bubendorf; C Ruiz
Journal:  Prostate Cancer Prostatic Dis       Date:  2014-01-28       Impact factor: 5.554

5.  Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate.

Authors:  Brett S Carver; Jennifer Tran; Anuradha Gopalan; Zhenbang Chen; Safa Shaikh; Arkaitz Carracedo; Andrea Alimonti; Caterina Nardella; Shohreh Varmeh; Peter T Scardino; Carlos Cordon-Cardo; William Gerald; Pier Paolo Pandolfi
Journal:  Nat Genet       Date:  2009-04-26       Impact factor: 38.330

6.  Polymorphisms in CYP17 and CYP3A4 and prostate cancer in men of African descent.

Authors:  Emanuela Taioli; Vestra Sears; Alexis Watson; Rafael E Flores-Obando; Maria D Jackson; Flora A Ukoli; Ilce M de Syllos Cólus; Pedro Fernandez; Norma McFarlane-Anderson; Elaine A Ostrander; Iara S Rodrigues; Janet L Stanford; Jack A Taylor; Marshall Tulloch-Reid; Camille C R Ragin
Journal:  Prostate       Date:  2012-11-05       Impact factor: 4.104

7.  Differences in frequency of ERG oncoprotein expression between index tumors of Caucasian and African American patients with prostate cancer.

Authors:  Philip Rosen; David Pfister; Denise Young; Gyorgy Petrovics; Yongmei Chen; Jennifer Cullen; Diana Böhm; Sven Perner; Albert Dobi; David G McLeod; Isabell A Sesterhenn; Shiv Srivastava
Journal:  Urology       Date:  2012-08-28       Impact factor: 2.649

8.  TMPRSS2-ERG fusion is frequently observed in Gleason pattern 3 prostate cancer in a Canadian cohort.

Authors:  Andrew D Darnel; Christopher J Lafargue; Robin T Vollmer; Jacques Corcos; Tarek A Bismar
Journal:  Cancer Biol Ther       Date:  2009-02-04       Impact factor: 4.742

9.  TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy.

Authors:  Anuradha Gopalan; Margaret A Leversha; Jaya M Satagopan; Qin Zhou; Hikmat A Al-Ahmadie; Samson W Fine; James A Eastham; Peter T Scardino; Howard I Scher; Satish K Tickoo; Victor E Reuter; William L Gerald
Journal:  Cancer Res       Date:  2009-02-03       Impact factor: 12.701

Review 10.  Genetic and molecular differences in prostate carcinogenesis between African American and Caucasian American men.

Authors:  James Farrell; Gyorgy Petrovics; David G McLeod; Shiv Srivastava
Journal:  Int J Mol Sci       Date:  2013-07-25       Impact factor: 5.923

View more
  7 in total

Review 1.  TMPRSS2:ERG Gene Fusions in Prostate Cancer of West African Men and a Meta-Analysis of Racial Differences.

Authors:  Cindy Ke Zhou; Denise Young; Edward D Yeboah; Sally B Coburn; Yao Tettey; Richard B Biritwum; Andrew A Adjei; Evelyn Tay; Shelley Niwa; Ann Truelove; Judith Welsh; James E Mensah; Robert N Hoover; Isabell A Sesterhenn; Ann W Hsing; Shiv Srivastava; Michael B Cook
Journal:  Am J Epidemiol       Date:  2017-12-15       Impact factor: 4.897

2.  RGS12 Is a Novel Tumor-Suppressor Gene in African American Prostate Cancer That Represses AKT and MNX1 Expression.

Authors:  Yongquan Wang; Jianghua Wang; Li Zhang; Omer Faruk Karatas; Longjiang Shao; Yiqun Zhang; Patricia Castro; Chad J Creighton; Michael Ittmann
Journal:  Cancer Res       Date:  2017-06-13       Impact factor: 12.701

3.  TMPRSS2-ERG gene fusion in Turkish patients with localized prostate cancer: results of radical prostatectomy specimens.

Authors:  Ömer Yılmaz; Ufuk Berber; Sezgin Okçelik; Hasan Soydan; Ferhat Ateş; Kenan Karademir
Journal:  Turk J Urol       Date:  2016-06

Review 4.  Ethnicity and ERG frequency in prostate cancer.

Authors:  Jason Sedarsky; Michael Degon; Shiv Srivastava; Albert Dobi
Journal:  Nat Rev Urol       Date:  2017-09-05       Impact factor: 14.432

5.  Autoantibodies against oncogenic ERG protein in prostate cancer: potential use in diagnosis and prognosis in a panel with C-MYC, AMACR and HERV-K Gag.

Authors:  Anshu Rastogi; Amina Ali; Shyh-Han Tan; Sreedatta Banerjee; Yongmei Chen; Jennifer Cullen; Charles P Xavier; Ahmed A Mohamed; Lakshmi Ravindranath; Jigisha Srivastav; Denise Young; Isabell A Sesterhenn; Jacob Kagan; Sudhir Srivastava; David G McLeod; Inger L Rosner; Gyorgy Petrovics; Albert Dobi; Shiv Srivastava; Alagarsamy Srinivasan
Journal:  Genes Cancer       Date:  2016-11

6.  Prevalence and clinical application of TMPRSS2-ERG fusion in Asian prostate cancer patients: a large-sample study in Chinese people and a systematic review.

Authors:  De-Pei Kong; Rui Chen; Chun-Lei Zhang; Wei Zhang; Guang-An Xiao; Fu-Bo Wang; Na Ta; Xu Gao; Ying-Hao Sun
Journal:  Asian J Androl       Date:  2020 Mar-Apr       Impact factor: 3.285

7.  Molecular profiling of radical prostatectomy tissue from patients with no sign of progression identifies ERG as the strongest independent predictor of recurrence.

Authors:  Wusheng Yan; Muhammad Jamal; Shyh-Han Tan; Yingjie Song; Denise Young; Yongmei Chen; Shilpa Katta; Kai Ying; Lakshmi Ravindranath; Tarah Woodle; Indu Kohaar; Jennifer Cullen; Jacob Kagan; Sudhir Srivastava; Albert Dobi; David G McLeod; Inger L Rosner; Isabell A Sesterhenn; Alagarsamy Srinivasan; Shiv Srivastava; Gyorgy Petrovics
Journal:  Oncotarget       Date:  2019-11-05
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.